1 / 13

Clinical Plan

Clinical Plan. Fran ç ois Charette, MD Chief Medical Officer. Bladder Cancer Population. 60,834. Advanced. 30%. (Death<12mos. if. metastatic. ). 202,781 cases annually. (EU & U.S. alone). Low. (Chemo & TURB). 50%. 70,974. Risk. Failure to. 30%. Intermediate. 141,947.

lovie
Télécharger la présentation

Clinical Plan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Plan François Charette, MD Chief Medical Officer

  2. Bladder Cancer Population 60,834 Advanced 30% (Death<12mos. if metastatic ) 202,781 cases annually (EU & U.S. alone) Low (Chemo & TURB) 50% 70,974 Risk Failure to 30% Intermediate 141,947 Superficial 70% 1st line Risk 30% tumor 42,584 12,775 High 20% 8,517 28,389 Risk + 70,973 21,292 Potential MCC patients 21 or 24 doses/patient (chemotherapy costs $500 - $1,000/dose) GLOBOCAN 2002

  3. MCC Clinical Development Plan • Simple rationale • Immunologic mechanism • Chemotherapeutic mechanism • Unmet needs • Issues with efficacy (chemotherapy, BCG) • Issues with safety (chemotherapy, BCG) • Successful Phase I/II studies completed • Majority BCG refractory patients

  4. Phase I-II Results • Safety Results • 9 patients withdrew from the study due to adverse events • (9/130 = 7%). BCG is between 20 and 30%. • Skin rash, possible relationship • Lower abdominal pain/fever/fatigue, related • Pyelonephritis (SAE), possible relationship • Pneumonia (SAE), after one dose of MCC, unknown relationship • Congestive heart failure (SAE), no relationship • Bladder pain, possibly drug related • Bladder pain, possibly drug related • Severe chest congestion, possibly drug related (8 mg) • Bladder pain, possibly drug related (8 mg)

  5. Phase I-II Results 109 patients: 81 received 4 mg, 28 received 8 mg4 mg at 6 months gave a CR of 35%8 mg at 6 months gave a CR of 46%

  6. Percentage of Complete Responders - prior BCG treated patients 50 45 40 35 30 % Complete 4 mg 25 Response 20 8mg 15 10 5 0 12 weeks 24/26 weeks Time post treatment Phase I-II Results 67 patients: 47 received 4 mg, 20 received 8 mg4 mg at 6 months gave a CR of 29.8%8 mg at 6 months gave a CR of 50%

  7. Phase I/II Study Conclusions • In patients with non-invasive bladder cancer, MCC was well tolerated (even in the presence of a disrupted epithelium). • Both studies demonstrated anticancer activity in patients with CIS of the urinary bladder as a second line therapy when patients failed to respond to standard immunotherapy (BCG) and/or chemotherapy, and as first line therapy in some patients • Efficacy was improved with the 8 mg dose compared to the 4 mg dose.

  8. Phase III Program -Growing body of pre-clinical evidence showing the efficacy of MCC -Good Phase II results showing: • Safety • Efficacy -Recognized treatment guidelines -Protocols developed in consultation with FDA -Targeting market access with broad indication -FDA has approved IND

  9. Phase III Program – Part One MCC in BCG refractory non-invasive bladder cancer patients Standard therapy: BCG given the opportunity to succeed in high risk of recurrence/ progression patients • No treatment offering responses over 20% • These patients are truly at high risk • After failure, patients referred for cystectomy

  10. Phase III Program – Part One MCC in BCG refractory non-invasive bladder cancer patients • Recruit in 12-18 months (105 patients) • Endpoint in 12-18 months • Data lock, analysis, report in 6 months • File with registration authorities

  11. Phase III Program – Part Two Randomized, double-blind, multi-centre trial comparing MCC to BCG as first line treatment for patients with non-invasive bladder cancer at high risk of recurrence or progression • Robust: 630 patients, blinded, worldwide • Comparator is the recognized therapy • Safety: superiority • Efficacy: superiority (or non-inferiority)

  12. Phase III Program – Part Two Randomized, double-blind, multi-centre trial comparing MCC to BCG as first line treatment for patients with non-invasive bladder cancer at high risk of recurrence or progression • Recruitment 2 years • Endpoint after 1-2 years for efficacy and safety • Data lock, analysis, report in 6 months • File with registration authorities

  13. Conclusion Population to treat (high risk bladder cancer) 0% 50% 100% 70% respond to BCG 30% refractory Refractory trial 40-60% refractory respond to MCC Comparative trial 82-88% respond to MCC = superiority to BCG

More Related